Ozempic vs. Wegovy: What's the Difference?

Here is one of the most common questions we hear at Truventa Medical: "What's the difference between Ozempic and Wegovy? They're both semaglutide, right?"

Yes — both medications contain the same active ingredient. But they are not interchangeable, and the differences between them matter significantly when it comes to FDA approval, dosing, cost, and what your insurance will cover. This guide breaks down everything you need to know so you can make an informed decision.

What Is Semaglutide?

Semaglutide is a GLP-1 receptor agonist — a class of medication that mimics a naturally occurring hormone called glucagon-like peptide-1. Under normal circumstances, your body releases GLP-1 after eating. It signals your brain that you're full, slows down stomach emptying so you feel satiated longer, and helps regulate blood sugar by prompting the pancreas to release insulin.

Manufactured by Novo Nordisk, semaglutide was first developed for type 2 diabetes management. Researchers quickly noticed patients were losing significant amounts of weight as a side effect — and clinical trials confirmed that at higher doses, the weight-loss effect was remarkable. This discovery led directly to Wegovy's development as a dedicated obesity treatment.

Side-by-Side Comparison

The table below covers the key differences between Ozempic and Wegovy. Pay special attention to the FDA approval, maximum dose, and price differences — these are where the two drugs diverge most significantly.

Why Doctors Prescribe Ozempic Off-Label for Weight Loss

The FDA's off-label prescribing rules in the United States allow physicians to prescribe any approved medication for conditions beyond its official approval — as long as there is clinical evidence supporting its use. Ozempic has extensive clinical trial data demonstrating meaningful weight loss results, making it a legitimate and commonly prescribed off-label treatment for obesity.

Many patients end up on Ozempic for weight loss because:

• Their insurance covers Ozempic for a diabetes diagnosis (even pre-diabetes or metabolic syndrome) but won't cover Wegovy
• Wegovy is out of stock in their area
• Their physician has a preference for the Ozempic dosing titration schedule
• They started on Ozempic and are seeing good results

At doses of 1–2mg weekly, Ozempic produces weight loss of approximately 12–15% of body weight over 12–18 months — meaningfully less than Wegovy's top-dose results, but still far more than previous obesity medications.

Wegovy's Higher 2.4mg Dose: Does the Extra 0.4mg Matter?

This is a genuinely interesting pharmacological question. Ozempic's maximum dose is 2mg/week; Wegovy's is 2.4mg/week. At first glance, a 0.4mg difference seems modest. But the clinical trial data tells a compelling story.

The STEP 1 trial — which specifically tested semaglutide 2.4mg for weight management — showed participants lost an average of 14.9% of body weight versus 2.4% for placebo over 68 weeks. Notably, about one-third of participants lost more than 20% of body weight at the 2.4mg dose.

Real-world data and head-to-head analyses suggest the additional 0.4mg contributes meaningfully to outcomes, particularly for patients who plateau at 2mg. The 2.4mg dose appears to maximize the drug's satiety signaling effect in the hypothalamus, reducing appetite more consistently across the patient population.

The Shortage Problem

Both Ozempic and Wegovy have faced significant supply shortages since 2022. The explosive demand for GLP-1 medications — driven partly by high-profile media coverage and celebrity use — far outpaced Novo Nordisk's manufacturing capacity. The FDA placed both drugs on its drug shortage list, creating a cascade of access problems: patients who had been stable on their medication couldn't refill prescriptions, and new patients couldn't start treatment.

These shortages opened the door for a legal alternative: compounded semaglutide. Under U.S. law, FDA-registered compounding pharmacies are permitted to produce compounded versions of medications that appear on the official drug shortage list — providing an important safety valve when brand-name supply is constrained.

Compounded Semaglutide: Same Molecule, Different Price

Compounded semaglutide contains the same active ingredient — semaglutide — as both Ozempic and Wegovy. It is produced by FDA-registered 503B outsourcing facilities (or 503A pharmacies for patient-specific compounding) under strict sterility and quality standards.

The clinical mechanism is identical: compounded semaglutide activates the same GLP-1 receptors, suppresses appetite through the same pathway, and produces weight loss results consistent with the clinical trial data for the same doses. The difference is entirely in the supply chain: rather than going through a pharmaceutical company's branded manufacturing and distribution system, the medication is prepared by a licensed compounding pharmacy and shipped directly to the patient.

It's worth noting what compounded semaglutide is not: it is not a generic (the patent on semaglutide has not expired), it is not FDA-approved as a finished product, and quality varies significantly between compounders. This is why choosing a reputable provider — one who sources from verified, FDA-registered facilities and provides certificates of analysis — is critically important.

Cost Comparison

The price difference between brand-name and compounded semaglutide is staggering, and it's the primary driver of patient interest in compounding:

• Ozempic (brand): ~$935/month without insurance
• Wegovy (brand): ~$1,349/month without insurance
• Compounded semaglutide at Truventa: Starting at $199/month

For patients without adequate insurance coverage — which is the majority, given how few plans cover obesity medications — the annual cost of Wegovy exceeds $16,000. Compounded semaglutide at $199–$349/month brings that total to $2,400–$4,188 annually. For many patients, this difference determines whether treatment is even possible.

Who Should Use Which? Decision Framework

Here's a practical guide for different scenarios:

Choose Ozempic brand if:

• You have type 2 diabetes and insurance covers Ozempic
• Your physician specifically recommends it for your clinical situation
• Wegovy is unavailable in your area

Choose Wegovy brand if:

• Your insurance covers obesity medications and you want maximum dose (2.4mg)
• You've plateaued at 2mg and need the additional titration step

Choose compounded semaglutide if:

• You don't have insurance coverage for obesity medications
• You want the same clinical results at a fraction of the cost
• You value the convenience of physician-supervised telemedicine care
• You want physician-monitored titration to the dose that works best for you

Getting Semaglutide Through Truventa Medical

At Truventa Medical, our approach to semaglutide is straightforward: you should have access to effective, physician-supervised weight loss treatment regardless of your insurance status. We prescribe compounded semaglutide sourced exclusively from FDA-registered 503B compounding facilities that provide certificates of analysis for every batch.

Our process is simple: complete a free online health intake, our licensed physicians review your case within 24 hours, and if appropriate, issue a prescription that's sent directly to your pharmacy for home delivery. Ongoing check-ins ensure your dose is optimized and your progress is on track.

You get the same molecule as Ozempic and Wegovy, physician supervision, and ongoing support — for a fraction of the brand-name price.